/PRNewswire/ Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced today the publication, in the Journal of Clinical Chemistry, of.
email article
Early patterns of circulating tumor cells (CTCs) from metastatic breast cancer correlated with treatment response and subsequent survival, according to a meta-analysis involving more than 4,000 patients.
Patients with negative CTC blood tests at baseline and a month later had median overall survival (OS) of almost 4 years. That compared with median OS of about 18 months for patients with two positive tests. Mixed results (positive/negative or negative/positive) were associated with OS in the middle.
Similar results emerged when stratified by cancer subtype, Wolfgang Janni, MD, PhD, of University Hospital Ulm in Germany, reported during the San Antonio Breast Cancer Symposium virtual meeting.
Circulating tumor cell dynamics linked with overall survival in patients with metastatic breast cancer
Early circulating tumor cell dynamics were associated with overall survival in patients with metastatic breast cancer, according to a meta-analysis presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11.
With the increasing number of treatment options available to patients with metastatic breast cancer, being able to predict and monitor treatment responses rapidly will be critical to aiding treatment decisions.
Wolfgang Janni, MD, PhD, professor, director of the women s clinic, Ulm University Hospital in Ulm, Germany
Responses to breast cancer treatment are typically monitored by conventional imaging, but this method requires time approximately three months, depending on the subtype before changes can be detected, Janni explained. We were interested in determining whether treatment response and prognosis could be predicted earlier using a simple blood test.